Intervention not reported
All‐cause mortality low risk of bias Mortality · patients with preventing hepatitis A.
The intervention showed no clear difference in all‐cause mortality low risk of bias Mortality (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality all included trials Mortality · patients with preventing hepatitis A.
The intervention showed no clear difference in all‐cause mortality all included trials Mortality (high certainty).
1 finding from 1 review
Intervention not reported
Hepatitis A‐related mortality · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Clinically apparent hepatitis A (inactivated HAV vaccines) low risk of bias trials Dienstag 1999 · patients with preventing hepatitis A.
The intervention leads to lower clinically apparent hepatitis A (inactivated HAV vaccines) low risk… (high certainty).
1 finding from 1 review
Intervention not reported
Lack of sero‐protection, (anti HAV IgG < 10mIU/L) (low risk of bias) Maiwald 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Lack of sero‐protection, (anti HAV IgG < 10mIU/L) (all included trials) Maiwald 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Lack of sero‐protection, (anti HAV IgG < 20mIU/L) (low risk of bias ) Maiwald 1997 · patients with preventing hepatitis A.
The intervention leads to lower lack of sero‐protection, (anti HAV IgG < 20mIU/L) (low risk of bias… (high certainty).
1 finding from 1 review
Intervention not reported
Lack of sero‐protection, (anti HAV IgG < 20mIU/L) (all included trials) Maiwald 1997 · patients with preventing hepatitis A.
The intervention may leads to lower lack of sero‐protection, (anti HAV IgG < 20mIU/L) (all included… (low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious local adverse events (low risk of bias) inactivated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious local adverse events (low risk of bias) inactivated HAV… (high certainty).
1 finding from 1 review
Intervention not reported
Non‐serious local adverse events (all included trials) ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious local adverse events (all included trials) ICH‐GCP 1997 (low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious systemic adverse events (low risk of bias) inactivated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious systemic adverse events (low risk of bias) inactivated… (high certainty).
1 finding from 1 review
Intervention not reported
Non‐serious systemic adverse events (all included studies) inactivated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious systemic adverse events (all included studies)… (low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious local adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐serious local adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Clinically apparent hepatitis A (inactivated HAV vaccines) all included trials Dienstag 1999 · patients with preventing hepatitis A.
The intervention may leads to lower clinically apparent hepatitis A (inactivated HAV vaccines) all… (low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious systemic adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐serious systemic adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Clinically apparent hepatitis A (live attenuated HAV vaccines) low risk of bias Dienstag 1999 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Clinically apparent hepatitis A (live attenuated HAV vaccines) all included trials Dienstag 1999 · patients with preventing hepatitis A.
It is very uncertain whether the intervention changes clinically apparent hepatitis A (live attenuated HAV vaccines) all… (very low certainty).
1 finding from 1 review
Intervention not reported
Clinically apparent hepatitis A (Dose of live attenuated HAV vaccine, titre >= TCID50 ) low risk of bias Dienstag 1999 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found